Avoid prescribing moderate to high-dose glucocorticoid treatment in rheumatic diseases without thorough risk-benefit assessment, a clear follow-up plan, and necessary preventive measures Avoid ordering MRI of the spine or joints unless it is likely to have diagnostic or therapeutic consequences Avoid prolonged treatment duration with bisphosphonates Avoid glucocorticoid joint injections without clear evidence of inflammation Avoid initiating biological treatment in axial spondyloarthritis without clear signs of inflammation